Skip to main navigation
Skip to search
Skip to main content
UT MD Anderson Cancer Center Home
Help & FAQ
Link opens in a new tab
Search content at UT MD Anderson Cancer Center
Home
Profiles
Research units
Equipment
Research output
Activities
Prizes
Fifth edition WHO classification: myeloid neoplasms
Xueyan Chen
, Nikhil Patkar
, Prashant Tembhare
, Subramanian Papagudi
, Cecelia Yeung
,
Rashmi Kanagal Shamanna
, Sumeet Gujral
, Brent Wood
, Kikkeri N. Naresh
Hematopathology
Research output
:
Contribution to journal
›
Review article
›
peer-review
6
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Fifth edition WHO classification: myeloid neoplasms'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Myeloid Neoplasms
100%
WHO Classification
100%
Fifth Edition
100%
Myelodysplastic Neoplasms
75%
Low-income
50%
Middle-income Countries
50%
Genetic Modification
25%
Next-generation Sequencing
25%
Flow Cytometry
25%
Tumor Protein p53 (TP53)
25%
Immunohistochemistry
25%
Hematological Malignancies
25%
Acute Myeloid Leukemia
25%
Molecular Diagnostics
25%
Diagnostic Tool
25%
Myeloproliferative Neoplasms
25%
Advanced Diagnostics
25%
Personalized Medicine
25%
Immunophenotyping
25%
Subclassification
25%
Biallelic
25%
Diagnostic Utility
25%
Risk Stratification
25%
Limited Access
25%
Genetic Abnormalities
25%
Disease Classification
25%
Hematopathologist
25%
Novel Entities
25%
Key Update
25%
Hematopathology
25%
Resource-rich
25%
Diagnostic Precision
25%
Hematolymphoid Tumors
25%
Improving Global Outcomes
25%
Precision Assessment
25%
Clonal Hematopoiesis
25%
Molecular Insights
25%
Prognostic Assessment
25%
Resource-constrained Environments
25%
Fourth Edition
25%
Genetic Insights
25%
Medicine and Dentistry
Neoplasm
100%
Genetics
57%
Clinician
14%
Gene Mutation
14%
Next Generation Sequencing
14%
Flow Cytometry
14%
Immunohistochemistry
14%
Molecular Diagnostics
14%
Acute Myeloid Leukemia
14%
Hematologic Malignancy
14%
Myeloproliferative Neoplasm
14%
Hematopoiesis
14%
Personalized Medicine
14%
Immunophenotyping
14%
Tumor
14%
Nosology
14%
Prognostic Assessment
14%
Risk Stratification
14%
Hematopathology
14%
Diagnosis
14%